To compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental therapy with etoposide, ifosfamide, and cisplatin (VIP) as primary treatment of men with advanced, disseminated germ cell tumors.
C URRENT MANAGEMENT of patients with germ cell tumor is driven by the availability of extraordinarily effective chemotherapy and the ability to sharply define prognosis.' Such prognostic and therapeutic luxuries have made observation in clinical stage I and resected stage II patients competitive strategies compared with the older standards of more extensive surgery, radiation therapy, or adjuvant chemotherapy. The reliable cure of patients with small-volume disseminated disease with four full courses of cisplatin, etoposide, and bleomycin (BEP) has led to shorterduration treatments (three courses) or four courses of two drugs (cisplatin and etoposide) as effective standard alternatives. 2 , 3 Patients with less extensive disseminated disease are almost always cured with brief, well-tolerated chemotherapy. The remaining controversies with regard to improved outcome or improved toxicity profile in this setting are still being tested in randomized trials in Europe.
Only in the less common situation of patients with advanced, poor-risk disease are there unanswered significant therapeutic questions. In this group of patients, there remains a substantial minority of patients who fail to obtain disease-free status or who die of their disease. In such patients, the current standard of treatment is four courses of BEP. Attempts to improve outcome in this group of patients have included increased cisplatin intensity, incorporation of early high-dose therapy and, more recently, increased 60%), failure-free at 2 years (VIP, 64%; BEP, 60%), and 2-year overall survival (VIP, 74%; SEP, 71%) were not significantly different between the two treatments. Grade 3 or worse toxicity, particularly hematologic and genitourinary toxicity, was significantly more common in patients who received VIP.
Conclusion: BEP and VIP produce comparable favorable response rate and survival in patients with poorrisk germ cell tumors. The substitution of ifosfamide for bleomycin, however, was associated with significantly greater toxicity. Four courses of BEP remain the standard treatment for advanced disseminated germ cell tumors.
J (Table 1 ). All primary sites and histologic subtypes were included, and patients of all ages and performance status were eligible. Exclusion criteria included prior chemotherapy or a baseline creatinine more than the upper limits of normal (unless because of obstructive uropathy). Informed consent was obtained from all patients before enrollment.
Before initiation of therapy, staging evaluations were performed to ascertain sites of involvement, degree of marker elevation, and underlying pulmonary and renal function. Computerized tomography of the chest and abdomen were obtained, along with determination of beta subunit human chorionic gonadotropin (HCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH). Additional studies were obtained as warranted by the clinical presentation.
Patients were randomly allocated to receive either the standard treatment with BEP or the investigational therapy with VIP. Patients were randomized in equal proportion to the two treatment arms and stratification was performed by cooperative group. The randomization used a permuted block strategy with blocks of size 6 for each participating institution. An accrual goal of 300 patients was chosen to ensure 140 assessable patients per treatment arm. This sample was selected to give at least a 90% probability of detecting a 20% difference in the rate of complete remission. It should be noted that the study design also gave a greater than 83% power to detect a 17.5% difference.
Patients assigned to the standard regimen received etoposide 100 mg/m 2 intravenously (IV) mixed with 500 mL of normal saline over a 30 to 60 minute period on days 1 through 5 of each course and bleomycin 30 U IV bolus injection weekly for 12 weeks. Cisplatin was begun after hydration with normal saline at 100 mL per hour for 12 hours. Cisplatin 20 mg/m 2 was given over a period of 30 to 60 minutes on days 1 through 5. Saline hydration at a rate of 100 mL per hour When granulocyte colony-stimulating factor (G-CSF) became available in December 1991, this drug was added to both arms of the treatment protocol (BEP arm, 5 pg/kg subcutaneously (SC) daily on days 7, 9 through 14, and 16 and 17; VIP arm, 5 pg/kg SC daily on days 7 through 16). The split schedule of G-CSF administration on the BEP arm was devised to avoid concomitant administration of bleomycin and G-CSE Thirty-four patients received G-CSF with an equal distribution among the two arms.
Patients on either arm were scheduled to receive four courses of therapy at 3-week intervals. Courses were to begin on schedule regardless of the degree of myelosuppression noted on the day of scheduled treatment. Patients who had received previous radiation therapy (11 patients with prior seminoma) had an initial dose reduction of etoposide and ifosfamide by 25%. There were no dose escalations allowed. Etoposide and ifosfamide doses were reduced by 25% for subsequent courses in any patient who developed granulocytopenic fever or thrombocytopenic bleeding with the previous course of chemotherapy. Bleomycin was discontinued if the patient manifested clinical or radiographic evidence of pulmonary fibrosis (rales or inspiratory lag) or significant deterioration of pulmonary diffusion capacity. Cisplatin dose was not modified for elevation of serum creatinine; however, if the serum creatinine rose to greater than 3 mg/dL, cisplatin treatment was delayed until the serum creatinine had dropped below this level.
After completion of the fourth course of chemotherapy, patients were evaluated for response. Previously abnormal radiologic studies were repeated, along with HCG, AFP, and LDH. Complete remission was declared if there was total disappearance of all radiographic and serologic evidence of disease. Patients with significant residual radiographic abnormalities and normal serum markers were to be evaluated for surgical resection of residual disease. Patients in whom total resection of residual disease was deemed possible were to be taken to surgery 4 to 6 weeks after the last cisplatin course.
Surgical findings were used to determine overall response. Patients found to have only fibrotic debris at surgery were coded as having a complete response to chemotherapy. Patients who had complete resection of only mature or immature teratoma were coded as being disease-free at the time of surgery (NED-teratoma). Patients who achieved a complete remission or who had total resection of teratoma received no further therapy. Patients in whom total resection of viable germ cell cancer was accomplished were declared to be disease-free at the time of surgery (NED-cancer). These patients received two additional courses of standard-dose cisplatin and etoposide (BEP arm) or etoposide, ifosfamide, and cisplatin (VIP arm).
Some patients obtained serologic complete remission but with persistent, often minor, radiographic abnormalities. Individual investigators often chose to observe such patients without surgery. Such patients were formally coded as partial remissions, but often remained with stable or improving imaging studies over a 2-year period and were coded as having a favorable response.
Patients with persistent elevation of the serum markers or disease so extensive as to preclude total resection were not taken to surgery. These patients were coded as having a partial response if there had been a greater than 50% reduction in the sum of the products of bidimension-NICHOLS ET AL ally measurable disease. Marker reduction of greater than 90% for at least 1 month was required to qualify as a serologic partial remission.
Statistical Analysis
The distribution of patient characteristics between the treatment arms was evaluated by the Fisher's exact test for balance. The exact Wilcoxon midrank test for ordered categorical outcome was used to compare the distribution of maximum toxicity grade between the two arms. Fisher's exact test was also used to analyze contingency tables of response. Survival curves were estimated by the method of Kaplan and Meier with differences assessed by the log-rank test. Logistic regression of response and proportional hazards regression of survival were used to identify simultaneously significant prognostic covariates based on the likelihood ratio test. as follows: AFP = ng/mL; HCG = mlU/mL; percent of patients on VIP and 60% of patients on BEP had not experienced treatment failure at the 2-year mark (P = .29; rsity; ULN, upper limit of normal. Fig 2) . Again, the Cox model identified extragonadal Table 5 gives the distribution of severe or worse toxicity by treatment for the 299 cases with toxicity information available. VIP had significantly higher overall hematologic toxicity (P < .001). There was a possible increase in 
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Copyright © 1998 by the American Society of Clinical Oncology. All rights reserved. NOTE. Only those patients assessable for favorable response are included in analysis. Units of measurement are as follows: AFP = ng/mL; HCG = mlU/mL; LDH = IU/L. genitourinary toxicities on the VIP arm; eight grade 3 toxicities on VIP versus one on BEP (P = .036). All of these toxicities were related to renal toxicity (creatinine > 3 times normal, BUN > 5 to 10 times normal) except for two patients on VIP with hematuria. Significant pulmonary toxicity was seen in seven patients on BEP and six patients on VIP. The details of the pulmonary toxicity were deemed to be particularly important in light of the use of bleomycin. Among the seven patients who received BEP who experienced pulmonary toxicity, three experienced difficulty with course 1 (postobstructive pneumonia, pulmonary embolus, and hemorrhage) and, in the two survivors of the first course, the patients continued bleomycin throughout the course of treatment. One patient had a diminished diffusion capacity on day 14 of course two and bleomycin was discontinued and three patients experienced toxicity with the fourth course and bleomycin was discontinued. Of the six patients on VIP who experienced pulmonary toxicity, four experienced toxicity with cycle one and one in conjunction with a febrile neutropenic event. There were eleven treatment-related deaths (five on VIP and six on BEP). For those patients who received VIP, four died of sepsis and one of intracranial hemorrhage with the second course of treatment. For patients who received BEP, one patient died of pulmonary hemorrhage with the first course (questionably related to treatment), two died of respiratory failure (courses one and four), and three died of sepsis.
DISCUSSION
This large intergroup randomized comparison of therapy with VIP to standard therapy with BEP failed to show a significant advantage for VIP in terms of favorable response, overall survival, or time to failure of treatment. Moreover, VIP was associated with significantly more myelosuppression, but hospitalization for neutropenic fever and early deaths were comparable for the two treatments. Three patients treated with BEP had early death secondary to pulmonary causes, which suggests a possible role for VIP in patients with baseline pulmonary compromise. Based on this analysis, we believe four courses of BEP remain standard therapy for advanced disseminated germ cell tumors.
Improvement in outcomes for patients with advanced disseminated disease has been incremental subsequent to the initial breakthrough of cisplatin-based combinations of the 1970s. The first demonstration of improved outcome in this group of patients came in the randomized trial of cisplatin, bleomycin, and either vinblastine or etoposide.
12 Fortunately, in this trial, not only was the etoposide-based treatment better tolerated, but BEP was significantly more effective in the poor-risk group of patients. Unfortunately, this trial reported in 1987 was the last significant therapeutic advance to be documented in mature phase III trials for patients who presented with poor-risk features.
The current results of this trial are consistent with other recent attempts to improve outcome in patients with ad- 4 The results were strikingly similar to the current study with 74% of patients alive and 62% progression-free. There was no survival advantage for high-dose cisplatin and, as expected, treatment with high-dose cisplatin combinations was significantly more toxic.
A further attempt to intensify therapy was reported by Droz et al. 5 , 13 Patients with poor-risk germ cell tumors by the Institut Gustave Roussy classification system were randomly allocated to receive the four-drug combination of high-dose cisplatin, vinblastine, bleomycin, and etoposide or a similar but abbreviated combination followed by a single high-dose cycle of cisplatin, etoposide, and cyclophosphamide followed by bone marrow reinfusion. Again, no advantage could be shown despite the high intensity and the addition of an oxazaphosphorone.
Most recently, in a trial designed similar to our current trial, the Medical Research Council of the Eastern Organization for Research and Treatment of Cancer (MRC/EORTC) compared BEP as standard therapy with an experimental treatment of BOP (schedule-dense bleomycin, oncovin, and cisplatin) followed by VIP. 6 Three hundred eighty patients were enrolled, the toxicity of the experimental arm was substantial, and, again, no improvement in survival was shown compared with standard BEP. Overall, the complete remission rate was 58% with an overall survival at 1.5 years of 70% in patients with poor-risk germ cell tumors. All these findings are consistent with an additional phase III trial in less-advanced disseminated germ cell tumors that has been reported, which compares standard therapy with a regimen containing ifosfamide. EORTC conducted a trial in patients defined as intermediate risk by their previously published criteria, in which 84 patients were randomized to a modified BEP regimen (etoposide 120 mg/m 2 on days 1, 3, and 5) or VIP.1 4 With a median follow-up of 2.5 years, there was no difference in efficacy between the two regimens in terms of complete response (BEP, 82%; VIP, 78%), progression-free survival (BEP, 88%; VIP, 85%), or overall survival BEP AND VIP FOR DISSEMINATED GERM CELL TUMORS (BEP, 97%, VIP, 93%). However, VIP produced significantly more leukopenia and thrombocytopenia. More recently, a large international effort to define prognostic factors has confirmed the poor outcome for certain patients with advanced germ cell tumors and defined subsets of patients with particularly poor outcomes with treatment. 15 This new system identifies prognostic subsets of patients with disseminated germ cell tumor based on readily available clinical parameters and degree of marker elevation. This prognostic model has been validated in large populations of uniformly treated patients and a very poorrisk group of patients have been identified, with advanced visceral nonpulmonary metastases, primary mediastinal nonseminoma, or very elevated serum HCG, AFP, or LDH. This subset of patients has an expected 5-year survival of less than 50%. It is in this subset that the current investigative efforts are being concentrated. In the United States, an intergroup trial is comparing standard therapy with BEP for four cycles to two cycles of BEP followed by high-dose carboplatin, etoposide, and cyclophosphamide for two cycles. It is also important to consider the availability of effective salvage treatments for patients who fail primary chemotherapy. Despite presenting with poor-risk features and the failure to achieve disease-free status or a relapse from complete remission, a substantial number of patients can be cured with subsequent interventions that include salvage chemotherapy (VIP), extensive surgeries, or high-dose chemotherapy with stem-cell support. The aggregate effect of these secondary strategies was seen in our study with a significantly higher percentage of patients alive than those who were rendered continuously free of disease by primary treatment.
On the whole, the current trial and other recently reported trials in advanced poor-risk germ cell tumors suggest that a therapeutic plateau has been reached. It seems unlikely that reconfiguration of currently available drugs or regimens will result in a significant improvement for this single remaining therapeutic challenge in disseminated germ cell tumors. Beyond this final intergroup effort to show the value of early incorporation of high-dose therapy, therapeutic advances will almost certainly require new agents and/or new understanding of the biology of these rare tumors and mechanism of resistance to treatment.
